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ABSTRACT
Background and aim Globally, nearly one in five people who inject drugs (PWID) are living with HIV, and the rate of
new HIV infections in PWID is increasing in some settings. Early diagnosis is crucial for effective HIV control. We reviewed
the evidence on the association between opioid agonist therapy (OAT) and HIV testing uptake among PWID.
Methods We conducted a systematic review searching MEDLINE, Scopus, Web of Science, Cochrane Central Register
of Controlled Trials and PsycINFO for studies published from January 2000 toMarch 2019. Reference lists and conference
proceedings were hand-searched. Observational and intervention studies were eligible for inclusion. Risk of bias was
assessed using the Risk of Bias in Non-Randomised Studies of Interventions (ROBINS-I) tool. Meta-analyses were
conducted using random-effects models. Results Of 13 373 records identified, 11 studies from Australia, Europe,
Malaysia and the United States were included. All studies had at least a serious risk of bias, largely due to confounding
and selection bias, making it difficult to draw causal conclusions from the evidence. Ten studies provided data on the
association between current OAT use and recent HIV testing. Six showed a positive association, while four provided little
evidence of an association: pooled odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.28–2.27. Looking at having
ever been on OAT and having ever been HIV tested, seven studies showed a positive association and three showed either
weak or no evidence of an association: pooled OR= 3.82, 95%CI = 2.96–4.95. Conclusions Opioid agonist therapymay
increase uptake of HIV testing among people who inject drugs, providing further evidence that opioid agonist therapy
improves the HIV treatment care cascade.
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INTRODUCTION
Globally, there are an estimated 15.6 million people aged
15–64 years who inject drugs (PWID) [1]. Blood-borne
virus infections from injecting drug use are a major
contributor to the global burden of disease [2,3]. There
are an estimated 2.8 million PWID living with HIV [1],
representing 18% of the global population of PWID and
contributing an estimated 4% of disability-adjusted life
years (DALYs) due to HIV [2].
In contrast to an overall 25% decline in global HIV
incidence between 2010 and 2017, the incidence among
PWID is increasing in some regions [4]. To reverse this
trend, there is a need to improve engagement in every
aspect of the HIV cascade of care [4]. Early diagnosis,
timely linkage to HIV care and initiation of anti-retroviral
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therapy (ART) are important, both for the health of the
individual and in reducing the risk of onward transmission
of HIV [5–8].
HIV prevention among PWID requires individual,
structural and combination approaches [9]. Harm
reduction programmes are endorsed by the World Health
Organization (WHO) as a key strategy in reducing morbid-
ity and mortality in PWID [4]. Global coverage of harm
reduction programmes for PWID improved between
2010 and 2017 [10,11]. However, in 2017 only approxi-
mately half of the 179 countries with evidence of injecting
drug use had any form of harm reduction programme [10].
Furthermore, only 34 countries report having targeted
programmes for HIV testing among PWID, and the
number of PWID receiving HIV tests or accessing ART
varies widely [10].
When integrated with HIV services, harm reduction in
the form of opioid agonist therapy (OAT) is associated with
improved initiation and adherence to ART and viral
suppression in PWID living with HIV [12,13]. OAT is also
associatedwith a reduction in risk of HIV [14] and hepatitis
C virus (HCV) acquisition [15]. However, to date, evidence
on the association between OAT use and HIV testing
uptake has not been synthesized, nor has the strength of
the evidence been critically assessed. We conduct the first
systematic review and meta-analysis of the association
between OAT use and HIV testing uptake among people
who have recently injected drugs. The aims of our review
are to assess: (1) the association between current or recent
OATuse andHIV testing in the last year; (2) the association
between ever having used OAT and ever having been HIV
tested; and (3) the risk of bias of the primary studies
included in the review.
METHODS
We registered our review protocol with the International
Prospective Register of Systematic Reviews (PROSPERO;
CRD42019131095). Our report of the review follows the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [16].
Eligibility criteria
Our review included studies that met the following criteria:
• Population: adults (> 15 years) with a current or recent
history of injection drug use (within the last year). We
excluded studies in prison populations, as OAT provision
in this setting is likely to be significantly different from
treatment delivered in other settings.
• Intervention: current or recent (within the last year)
OAT use was the primary intervention of interest. OAT
use ever was the secondary intervention of interest. We
included studies on OAT (both methadone and
buprenorphine), irrespective of whether they were
delivered in isolation or in conjunction with other harm
reduction interventions.
• Comparator: no current OAT use was the primary
intervention of interest; no history of OAT use was the
secondary intervention.
• Outcome: recent (within the last year) HIV antibody
testing was the primary outcome of interest. Ever HIV
antibody testing was the secondary outcome.
• Study design: randomized and non-randomized trials
and observational studies with a sample size > 40.
Search strategy
We searched MEDLINE, Scopus, Web of Science, Cochrane
Central Register of Controlled Trials and PsycINFO
databases for studies published from January 2000 to
March 2019. We used a combination of Subject
Headings (e.g. MeSH terms) and free-text key words.
Search terms included HIV, testing, opioid substitution
and injecting drug use (see Appendix SI for search strat-
egy). No restriction was placed on language or publication
status. We also searched conference abstracts from the
Annual Conference on Retroviruses and Opportunistic
Infections and the International AIDS Conference for the
same period.
We hand-searched the reference lists of papers selected
for inclusion in our review and relevant review papers.
Forward citation searches were conducted using Web of
Science, Google Scholar and Scopus. We also sought data
from known repositories of data on PWID and contacted
authors for supplementary data where required.
Study selection
After the removal of duplicates, titles and abstracts were
screened by one reviewer, with 10% checked by a second
reviewer. Full texts were retrieved for records identified as
potentially eligible and were independently reviewed by
two authors using pre-defined eligibility criteria. Discrep-
ancies were resolved through discussion, with a third
reviewer consulted as necessary.
Data extraction and synthesis
Data were independently extracted by two reviewers into a
pre-defined and piloted Microsoft Excel database. Any
discrepancies were identified and resolved. Data extracted
included study design, study period, country, method of
recruitment, inclusion criteria, sample size, age, gender,
OAT type and HIV testing (either self-reported or docu-
mented in medical or other records). Unadjusted and
adjusted odds ratios (ORs) and 95% confidence intervals
(CIs) were extracted or calculated for each study. Where
data were insufficient or missing, we contacted the study
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authors. Where there was more than one publication from
the same study, the one with the most comprehensive and
relevant data to our primary outcome was selected as the
main information source. Where a manuscript did not
present the specific data that we required, but indicated
that this may have been collected, this was requested from
the study authors.
Statistical heterogeneity was assessed using the
Cochran χ2 test (Q-test), with the I2 statistic used to assess
the percentage of variability between studies due to hetero-
geneity rather than sampling error. Due to the presence of
between-study variability, summary outcomes were calcu-
lated using random-effects meta-analysis. Prediction inter-
vals were calculated to reflect heterogeneity by indicating
the interval within which the true effects of 95% of any
similar future studies would be expected to fall [17,18].
Logit-transformed outcome estimates were used in all
meta-analyses and the estimates were back-transformed
for reporting. Where available, ORs adjusted for all key
confounders throughout the whole study data set were
used in the meta-analyses, otherwise unadjusted estimates
were used. A fixed continuity correction of 0.5 was applied
where the outcome of a study was 0 or 100%.
Meta-regression was planned to assess factors contributing
to heterogeneity across studies. All analyses were con-
ducted using the metan package in Stata version 15 [19].
Assessment of risk of bias
We assessed the risk of bias using the ROBINS-I tool (‘Risk
of Bias in Non-randomised Studies – of Interventions’). The
tool assesses bias across seven domains: confounding,
selection of participants, classification of interventions,
deviations from intended interventions, missing data,
measurement of the outcome and selection of the reported
result. Assessments are made at the outcome rather than
study level, so for studies that provided data on both the
primary and secondary outcome a risk of bias assessment
were conducted for each. Studies were judged as having
‘low’, ‘moderate’, ‘serious’ or ‘critical’ risk of bias for each
domain, and the overall risk of bias was then derived. A
study was judged as being at low risk of bias overall if it
was at low risk of bias for all domains, at moderate risk of
bias if it was at a low or moderate risk of bias for all
domains, at serious risk of bias if it was at serious risk of bias
for at least one domain but not at critical risk of bias in any
domain and at critical risk of bias if it was judged to be at
critical risk of bias in at least one domain [20].
Risk of bias assessments were undertaken by two
reviewers independently with any discrepancies resolved
through discussion, and the involvement of a third
reviewer as necessary. A priori key confounders were age,
gender, time since last injection drug use and markers of
severity of addiction (e.g. homelessness, stimulant use in
conjunction with injected opioids.)
RESULTS
Search results
The electronic database searches identified 13 214 records,
with a further 159 retrieved from other sources (totalling
13 373). We contacted 69 study authors of the 318
full-text screened studies to request supplementary data.
In total, 11 studies were eligible; one study with data as
published [21] and 10 with supplementary data requested
from authors [22–31] (Fig. 1). In four instances, data on
OAT use and HIV testing was specifically extracted for
inclusion in our meta-analysis from routinely collected
cross-sectional survey data [26,32–34].
All studies were cross-sectional, except for one random-
ized controlled trial. The number of participants in each
study ranged from 80 to 19 481. A total of 53 012 individ-
uals were included in our analysis, the majority (73%) of
whom are male. The mean age of participants within
studies ranged from 23.4 to 39.4 years (Table 1).
Studies were based in nine countries: Australia, Croatia,
Malaysia, Ukraine, the four countries in the United
Kingdom and the United States. Individuals from the
United Kingdom (52.7%, n = 27925) and Ukraine
(38.9%, n = 20 644) comprised the majority of the sample.
Risk of bias
All studies were assessed as being at serious risk of bias,
primarily due to the risk of confounding and selection bias.
In the absence of any strong evidence indicating which, if
any, factors are likely to confound the association between
OAT use and HIV testing we judged studies presenting
unadjusted analyses only to be at serious rather than
critical risk of bias due to confounding. Two studies
provided adjusted estimates for both the primary and
secondary analyses and these were assessed as being at
moderate risk of bias due to confounding, although at seri-
ous risk of bias overall [26,28]. One study provided
adjusted estimates for a proportion of their data [32]. As
this study remained at a serious risk of bias and provided
similar estimates to the unadjusted data (more information
is presented in Appendix S2), we chose to use the larger,
unadjusted data to increase the power in our analyses. A
further study provided adjusted analyses for the secondary
analysis but remained at serious risk of bias due to con-
founding, as only age and sex were adjusted for [21]. Con-
sequently, it was not appropriate to conduct sensitivity
analyses to assess how excluding studies at serious risk of
bias influenced the findings. Where there was sufficient in-
formation to make an assessment, risk of bias for all other
domains was low or moderate (Figs 2 and 3).
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Impact of OAT on HIV testing uptake
Ten studies provided data for our primary analysis: the im-
pact of current OAT use on HIV testing uptake in the previ-
ous year (Table 2). Six showed a positive association, while
four provided little evidence of an association; ORs ranged
from 1.03 to 3.58 across studies. Two adjusted estimates
were available for the complete study population and were
included in the meta-analysis [26,28] (see Appendix S2
for comparisons of unadjusted and adjusted effect esti-
mates). The pooled OR across all 10 studies was 1.71
(95% CI = 1.28–2.27, prediction interval = 0.66–4.43).
Inconsistency of results across studies was high
(I2 = 93.9, P < 0.001). No meta-regression was under-
taken due to the small number of studies and the lack of
clear candidate factors for explaining heterogeneity
(Fig. 4).
Ten studies provided data for our secondary analysis:
the impact of ever using OATon uptake of HIV testing ever
(Table 2). Seven studies showed a positive association and
three showed either weak or no evidence of an association.
Two adjusted estimates were available for inclusion in the
meta-analysis (Appendix S2). The pooled OR among all
studies was 3.82 (95% CI = 2.96–4.95, prediction
interval = 1.69–8.65). Heterogeneity was again high
(I2 = 87.2%, P < 0.001) (Fig. 5).
Figure 1 Study selection flow-chart
4 Claire F. Ferraro et al.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































OAT and HIV testing: systematic review 5
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
DISCUSSION
Our comprehensive review found evidence from published
and unpublished observational studies and one random-
ized controlled trial that current OAT use is associated with
an increased uptake of HIV testing in the last year among
PWID. We also found evidence to suggest that people
who had ever taken OAT were more likely to have ever
been tested for HIV.
This is the first systematic review, to our knowledge, of
the impact of OAT on HIV testing uptake among PWID.
Our results are consistent with findings of other studies
demonstrating the benefits of OAT use in reducing harms
across multiple health outcomes for people who are
Figure 2 Risk of bias assessments for studies assessing current opioid agonist therapy (OAT) use and HIV testing in the previous year (primary anal-
ysis). PHW = Public Health Wales; PHE = Public Health England; UAM = unlinked anonymous monitoring; NESI = Needle Exchange Surveillance
Initiative; HPS = Health Protection Scotland. Figure created using robvis [35]
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opioid-dependent [36]. OAT use has been shown to im-
prove engagement in HIV treatment uptake, adherence
and viral suppression, as well as engagement in hepatitis
C testing and treatment [12,37,38]. OAT use is also associ-
atedwith a reduced risk of HIVandHCV infections [14,15].
Reasons for the observed positive association between
OAT use and HIV testing uptake are likely to be multi-
factorial. That some OAT programmes require entrants to
be HIV tested may be one explanation [39]. The character-
istics and preferences of those seeking OAT may also play a
role; entry into an OAT programme is indicative of an indi-
vidual’s level of engagement with health-care providers
with regard to drug use and associated health-care needs.
Furthermore, people in OAT will probably also have in-
creased opportunities to be offered HIV testing, although
global data on HIV testing programmes for PWID are
Figure 3 Risk of bias assessments for studies assessing opioid agonist therapy (OAT) use ever and HIV testing ever (secondary analysis).
PHW=Public HealthWales; PHE = Public Health England, UAM= unlinked anonymous monitoring; NESI =Needle Exchange Surveillance Initiative;
HPS = Health Protection Scotland. Figure created using robvis [35].
OAT and HIV testing: systematic review 7
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scarce [10]. Finally, the multiple benefits of OAT use, such
as improved functional outcomes [40] and reductions in
injecting risk behaviour [39], criminal activity [41],
overdose and all-cause mortality [42], may lead to better
engagement in services and a greater readiness to test,
and be treated, for HIV.
The major strength of our review is that we included
several sources of unpublished data and completed second-
ary analyses of data that have not previously been applied
to this research question. We recognize that publication
bias may be an issue—although we screened more than
13 000 study reports for eligibility, there may be relevant
Figure 5 Meta-analysis of ever opioid agonist therapy (OAT) use and HIV testing ever among people who inject drugs (PWID) who have recently
injected drugs (secondary analysis). PHW= Public HealthWales; NESI = Needle Exchange Surveillance Initiative; HPS = Health Protection Scotland;
UAM = unlinked anonymous survey; PHE = Public Health England; OR = odds ratio. *Effect estimate for this study is adjusted for age, sex, injection
duration, homelessness, injection of stimulants and imprisonment
Figure 4 Meta-analysis of current opioid agonist therapy (OAT) use and HIV testing in the previous year among people who inject drugs (PWID)
who have recently injected drugs (primary analysis). PHW = Public Health Wales; NESI = Needle Exchange Surveillance Initiative; HPS = Health
Protection Scotland; UAM = unlinked anonymous survey; PHE = Public Health England; OR = odds ratio. *Effect estimates for these two studies
are adjusted for age, sex, injection duration, homelessness, injection of cocaine/stimulants and imprisonment
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data sets that were not identified through our searches be-
cause authors had not published data pertaining to OAT
use and HIV testing. There is also a small risk that we
missed some studies due to lack of complete duplicate
screening at title and abstract screening. However, of the
10% of studies screened in duplicate on title and abstract
there were no important discrepancies. All studies that
reached the full text screening stage were screened in
duplicate.
The findings presented in this review are limited by the
relatively small number of studies eligible for inclusion.
The majority of data in the review originated from either
the United Kingdom or Ukraine, which may limit the
generalizability of the findings. All studies were conducted
in urban areas, and excluded prison populations where
drug injecting and HIV testing practices may differ from
other settings [43,44].
Furthermore, the serious risk of bias identified in all the
studies included in this review means that findings should
be interpreted with caution, and that estimates of associa-
tion should not be interpreted as convincing evidence of
causality. Lack of adjustment for confounding factors,
including age, gender, time since last injection drug use,
markers of severity of addiction and bias in the selection
of participants, were the main reasons that studies were
assessed as being at serious risk of bias. However, the three
studies providing effect estimates for the primary analysis
that were adjusted for all important confounders were
similar to the unadjusted estimates, which may suggest
that these factors do not strongly influence the association
between OAT use and HIV testing.
The temporality of the association between exposure
and outcome is also an issue, as the majority (n = 10) of
studies included in our review were cross-sectional. We
cannot, therefore, assume that OAT use commenced
before, rather than after, HIV testing in those studies. To
try to minimize this issue we chose current OAT use and
HIV testing in the last year as our primary analysis. In
future studies it would be interesting and informative to
collect data on both the date that OAT started and the date
of HIV testing to more clearly understand the temporality
of the association.
It was not possible to explore reasons for heterogeneity
across the studies in our analysis. It is likely that the char-
acteristics of the study participants and the different
settings in which studies were conducted can explain
much of the heterogeneity observed. For example, there
are variations in both HIV prevalence and OAT coverage
by setting. Estimated HIV prevalence among PWID in re-
gions where our included studies were conducted vary be-
tween 1.1% (95% CI = 0.8–1.4) in Australasia and 24.7%
(95% CI = 15.6–33.9) in eastern Europe [1], while OAT
coverage varies from one to two OATclients per 100 PWID
in eastern Europe to 46–95 in western Europe [10].
It was not possible to explore differences in the associa-
tion between OAT use and HIV testing by gender, due to a
lack of disaggregated data. Evidence from some countries
suggests that HIV is more prevalent in women who inject
drugs than in men [45], and females may face social,
structural and psychological barriers to accessing harm
reduction services which their male counterparts do not
experience [46]. Further studies to explore and address
gender differences in the access and outcomes for harm
reduction services for PWID would be a welcome addition
to the evidence base.
Finally, HIV testing uptake in people who inject stimu-
lants rather than opioids, and consequentially for whom
OAT is not indicated, may differ in HIV testing behaviour.
This may be due to the different risk factors associated with
stimulant, rather than heroin injection, including the
sexual transmission of HIV within the men who have sex
with men (MSM) community [47]. However, although
some PWID in the studies included in our review may be
injecting stimulants rather than opioids, a recent
systematic review on OAT use and hepatitis C testing and
treatment noted that the proportion of PWIDwho reported
ever using opioids was 95–100%, indicating that this
issue is unlikely to have substantially biased our
findings [38].
For health-care policymakers and practitioners seeking
to reduce the harms associatedwith injecting drug-use, the
findings of this study provide further support for OAT as a
critical component of harm reduction. Together with
evidence on the benefits of OAT on the HIV treatment care
cascade [12] our findings suggest that, in addition to the
benefits of OAT across multiple health domains [36], OAT
may also improve HIV testing and treatment among PWID.
OAT programmes may also support work in settings where
HIV testing programmes for PWID [10] are in development
or do not comply with the recommendations made by the
WHO [48]. However, even where OAT and HIV testing
programmes are well established, there is more work to
do to understand barriers and enablers to HIV testing
uptake. Recent findings from the United Kingdom, for
example, suggest that there are still many PWID who are
accessing health and harm reduction services and yet
report no history of HIV testing [49].
CONCLUSIONS
Our findings indicate that OATmay increase uptake of HIV
testing among PWID, providing further evidence of the
benefits of OAT use on the HIV treatment and care cascade.
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